| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 26 | 2024 | 1270 | 3.370 |
Why?
|
| Stroke Volume | 14 | 2024 | 481 | 3.000 |
Why?
|
| Coronary Circulation | 5 | 2024 | 131 | 2.240 |
Why?
|
| Pulmonary Embolism | 4 | 2021 | 237 | 1.640 |
Why?
|
| Cardiac Catheterization | 10 | 2019 | 316 | 1.630 |
Why?
|
| Ventricular Function, Left | 9 | 2021 | 617 | 1.550 |
Why?
|
| Ventricular Dysfunction, Left | 9 | 2018 | 333 | 1.430 |
Why?
|
| Microcirculation | 4 | 2024 | 105 | 1.420 |
Why?
|
| Coronary Artery Disease | 9 | 2024 | 373 | 1.420 |
Why?
|
| Aortic Valve Stenosis | 5 | 2020 | 149 | 1.350 |
Why?
|
| Transcatheter Aortic Valve Replacement | 4 | 2020 | 58 | 1.310 |
Why?
|
| Microvessels | 2 | 2019 | 69 | 1.230 |
Why?
|
| Vascular Calcification | 2 | 2019 | 51 | 1.180 |
Why?
|
| Coronary Vessels | 4 | 2024 | 194 | 1.120 |
Why?
|
| Thrombolytic Therapy | 3 | 2018 | 246 | 1.050 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2019 | 69 | 0.980 |
Why?
|
| Benzazepines | 6 | 2012 | 64 | 0.950 |
Why?
|
| Radial Artery | 4 | 2019 | 33 | 0.900 |
Why?
|
| Hospitalization | 7 | 2015 | 898 | 0.890 |
Why?
|
| Renal Insufficiency | 3 | 2015 | 97 | 0.840 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2019 | 67 | 0.780 |
Why?
|
| Heart Diseases | 2 | 2016 | 306 | 0.700 |
Why?
|
| Heart-Assist Devices | 5 | 2021 | 822 | 0.700 |
Why?
|
| Coronary Artery Bypass | 3 | 2019 | 239 | 0.690 |
Why?
|
| Heart Arrest | 3 | 2018 | 280 | 0.680 |
Why?
|
| Electrocardiography | 2 | 2019 | 498 | 0.660 |
Why?
|
| Ventricular Pressure | 3 | 2021 | 43 | 0.650 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2019 | 15 | 0.650 |
Why?
|
| Hemodynamics | 5 | 2024 | 739 | 0.650 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2019 | 99 | 0.650 |
Why?
|
| Coronary Occlusion | 1 | 2019 | 7 | 0.650 |
Why?
|
| Catheterization, Peripheral | 1 | 2019 | 60 | 0.640 |
Why?
|
| Treatment Outcome | 22 | 2024 | 8367 | 0.630 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 64 | 0.630 |
Why?
|
| Atherectomy, Coronary | 1 | 2018 | 2 | 0.620 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 260 | 0.620 |
Why?
|
| Cardiac Catheters | 1 | 2018 | 13 | 0.620 |
Why?
|
| Patient Readmission | 4 | 2017 | 357 | 0.610 |
Why?
|
| Aged | 34 | 2024 | 19380 | 0.610 |
Why?
|
| Humans | 69 | 2024 | 90539 | 0.590 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 4 | 2012 | 27 | 0.570 |
Why?
|
| Echocardiography | 5 | 2018 | 947 | 0.560 |
Why?
|
| Triage | 1 | 2018 | 118 | 0.560 |
Why?
|
| Myocardium | 3 | 2018 | 574 | 0.550 |
Why?
|
| Etiocholanolone | 4 | 2009 | 5 | 0.550 |
Why?
|
| Cardio-Renal Syndrome | 2 | 2019 | 6 | 0.550 |
Why?
|
| Device Removal | 1 | 2018 | 169 | 0.540 |
Why?
|
| Female | 46 | 2024 | 46831 | 0.540 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 170 | 0.530 |
Why?
|
| Male | 43 | 2024 | 42909 | 0.520 |
Why?
|
| Middle Aged | 38 | 2024 | 26305 | 0.520 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 231 | 0.520 |
Why?
|
| Postoperative Complications | 2 | 2017 | 2341 | 0.510 |
Why?
|
| Retrospective Studies | 16 | 2021 | 9310 | 0.500 |
Why?
|
| Endoscopy | 1 | 2019 | 353 | 0.500 |
Why?
|
| Point-of-Care Systems | 4 | 2008 | 146 | 0.490 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 6808 | 0.480 |
Why?
|
| Creatinine | 1 | 2015 | 295 | 0.480 |
Why?
|
| Cardiomyopathies | 1 | 2017 | 269 | 0.460 |
Why?
|
| Kidney | 2 | 2019 | 1150 | 0.460 |
Why?
|
| Coronary Angiography | 7 | 2023 | 246 | 0.440 |
Why?
|
| Cardiotonic Agents | 3 | 2009 | 91 | 0.440 |
Why?
|
| Thrombosis | 1 | 2016 | 312 | 0.420 |
Why?
|
| Neurotransmitter Agents | 2 | 2019 | 108 | 0.420 |
Why?
|
| Ischemia | 3 | 2020 | 254 | 0.410 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2019 | 2692 | 0.410 |
Why?
|
| Risk Factors | 7 | 2021 | 5578 | 0.370 |
Why?
|
| Popliteal Artery | 2 | 2020 | 29 | 0.350 |
Why?
|
| Myocardial Ischemia | 2 | 2023 | 165 | 0.350 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 1741 | 0.340 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 1129 | 0.340 |
Why?
|
| Absorbable Implants | 2 | 2020 | 37 | 0.340 |
Why?
|
| Angioplasty, Balloon | 2 | 2020 | 98 | 0.330 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2019 | 197 | 0.330 |
Why?
|
| Shock, Cardiogenic | 2 | 2024 | 124 | 0.320 |
Why?
|
| Peripheral Arterial Disease | 2 | 2020 | 98 | 0.310 |
Why?
|
| Vascular Resistance | 2 | 2019 | 103 | 0.310 |
Why?
|
| Vasopressins | 1 | 2008 | 50 | 0.310 |
Why?
|
| Prognosis | 9 | 2019 | 3810 | 0.310 |
Why?
|
| Weight Gain | 1 | 2009 | 120 | 0.310 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 190 | 0.300 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2019 | 357 | 0.290 |
Why?
|
| Amyloidosis | 1 | 2009 | 130 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 854 | 0.280 |
Why?
|
| Biomarkers | 6 | 2019 | 1797 | 0.280 |
Why?
|
| Double-Blind Method | 7 | 2024 | 1723 | 0.280 |
Why?
|
| Angina Pectoris | 2 | 2023 | 29 | 0.280 |
Why?
|
| Spironolactone | 2 | 2021 | 12 | 0.270 |
Why?
|
| Pulmonary Wedge Pressure | 5 | 2021 | 116 | 0.270 |
Why?
|
| Cardiovascular Agents | 3 | 2012 | 55 | 0.260 |
Why?
|
| Hospital Mortality | 2 | 2021 | 416 | 0.260 |
Why?
|
| Heart | 4 | 2019 | 580 | 0.250 |
Why?
|
| Causality | 2 | 2017 | 80 | 0.240 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2019 | 224 | 0.240 |
Why?
|
| Splanchnic Nerves | 1 | 2024 | 8 | 0.240 |
Why?
|
| Prospective Studies | 7 | 2019 | 4345 | 0.240 |
Why?
|
| Echocardiography, Three-Dimensional | 3 | 2019 | 521 | 0.230 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 3 | 2009 | 80 | 0.230 |
Why?
|
| Myocardial Bridging | 1 | 2023 | 5 | 0.220 |
Why?
|
| Time Factors | 6 | 2020 | 5364 | 0.220 |
Why?
|
| Exercise Test | 1 | 2024 | 168 | 0.210 |
Why?
|
| Hypothermia, Induced | 1 | 2024 | 82 | 0.210 |
Why?
|
| Blood Pressure | 4 | 2008 | 906 | 0.210 |
Why?
|
| Vena Cava, Inferior | 4 | 2008 | 148 | 0.210 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 3 | 2021 | 18 | 0.210 |
Why?
|
| Kidney Function Tests | 2 | 2015 | 116 | 0.200 |
Why?
|
| Myocardial Revascularization | 2 | 2014 | 30 | 0.190 |
Why?
|
| Heart Atria | 3 | 2016 | 285 | 0.190 |
Why?
|
| Comorbidity | 2 | 2017 | 955 | 0.190 |
Why?
|
| Catheters | 1 | 2021 | 87 | 0.180 |
Why?
|
| Lower Extremity | 1 | 2021 | 89 | 0.180 |
Why?
|
| Equipment Failure | 2 | 2018 | 123 | 0.180 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2020 | 5 | 0.180 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2782 | 0.180 |
Why?
|
| Risk Assessment | 6 | 2020 | 2335 | 0.170 |
Why?
|
| Equipment Design | 3 | 2018 | 423 | 0.170 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1882 | 0.170 |
Why?
|
| Punctures | 1 | 2019 | 30 | 0.170 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2019 | 5 | 0.170 |
Why?
|
| Fibrosis | 2 | 2020 | 238 | 0.170 |
Why?
|
| Ventricular Remodeling | 1 | 2020 | 108 | 0.170 |
Why?
|
| Survival Rate | 3 | 2020 | 1899 | 0.170 |
Why?
|
| Mitral Valve | 2 | 2018 | 267 | 0.160 |
Why?
|
| Sutureless Surgical Procedures | 1 | 2019 | 6 | 0.160 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 746 | 0.160 |
Why?
|
| Septal Occluder Device | 1 | 2019 | 51 | 0.160 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2019 | 70 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2009 | 53 | 0.160 |
Why?
|
| Chronic Disease | 2 | 2019 | 959 | 0.160 |
Why?
|
| United States | 5 | 2019 | 7138 | 0.160 |
Why?
|
| Illinois | 2 | 2018 | 491 | 0.160 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 3691 | 0.160 |
Why?
|
| Radiation Dosage | 1 | 2019 | 230 | 0.160 |
Why?
|
| rho-Associated Kinases | 1 | 2020 | 160 | 0.150 |
Why?
|
| Hospitals | 1 | 2021 | 308 | 0.150 |
Why?
|
| Drug-Eluting Stents | 1 | 2018 | 19 | 0.150 |
Why?
|
| Fatal Outcome | 1 | 2019 | 298 | 0.150 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2018 | 24 | 0.150 |
Why?
|
| Disease Progression | 2 | 2015 | 1485 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2019 | 111 | 0.150 |
Why?
|
| Atrial Function, Left | 1 | 2018 | 53 | 0.150 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2018 | 47 | 0.150 |
Why?
|
| Monocytes | 1 | 2019 | 222 | 0.150 |
Why?
|
| Myocardial Infarction | 3 | 2014 | 385 | 0.150 |
Why?
|
| Hydroxyethylrutoside | 1 | 2017 | 1 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 281 | 0.140 |
Why?
|
| Blood Circulation | 1 | 2017 | 30 | 0.140 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 94 | 0.140 |
Why?
|
| Heart Massage | 1 | 2017 | 12 | 0.140 |
Why?
|
| Allografts | 1 | 2018 | 190 | 0.140 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 182 | 0.140 |
Why?
|
| Renal Veins | 1 | 2017 | 29 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3485 | 0.130 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 40 | 0.130 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2018 | 198 | 0.130 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 28 | 0.130 |
Why?
|
| Macrophages | 1 | 2019 | 585 | 0.130 |
Why?
|
| Health Status | 1 | 2018 | 370 | 0.130 |
Why?
|
| Ultrasonography | 5 | 2009 | 722 | 0.130 |
Why?
|
| Upper Extremity | 1 | 2016 | 57 | 0.130 |
Why?
|
| Blood Flow Velocity | 2 | 2014 | 199 | 0.120 |
Why?
|
| Catheterization | 1 | 2017 | 239 | 0.120 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2015 | 11 | 0.120 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 100 | 0.120 |
Why?
|
| Incidence | 2 | 2017 | 1593 | 0.120 |
Why?
|
| Coronary Aneurysm | 1 | 2015 | 16 | 0.120 |
Why?
|
| Quality of Life | 1 | 2023 | 1687 | 0.120 |
Why?
|
| Hemostatic Techniques | 1 | 2014 | 18 | 0.120 |
Why?
|
| Hemoptysis | 1 | 2014 | 24 | 0.120 |
Why?
|
| Aortic Valve | 1 | 2017 | 251 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1607 | 0.120 |
Why?
|
| Contrast Media | 1 | 2019 | 1085 | 0.120 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 482 | 0.110 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2014 | 12 | 0.110 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 85 | 0.110 |
Why?
|
| Chicago | 2 | 2017 | 1441 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2017 | 697 | 0.110 |
Why?
|
| Heart Ventricles | 1 | 2019 | 791 | 0.110 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2015 | 89 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 185 | 0.110 |
Why?
|
| Urbanization | 1 | 2013 | 14 | 0.110 |
Why?
|
| Developed Countries | 1 | 2013 | 25 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1085 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1873 | 0.110 |
Why?
|
| Sensitivity and Specificity | 4 | 2017 | 2019 | 0.110 |
Why?
|
| Ventricular Dysfunction | 1 | 2013 | 28 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 722 | 0.110 |
Why?
|
| Graft Rejection | 1 | 2019 | 1084 | 0.110 |
Why?
|
| Software | 1 | 2017 | 669 | 0.100 |
Why?
|
| North America | 1 | 2013 | 188 | 0.100 |
Why?
|
| Canada | 1 | 2013 | 201 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2015 | 327 | 0.100 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 228 | 0.100 |
Why?
|
| Heart Transplantation | 1 | 2018 | 744 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 860 | 0.100 |
Why?
|
| Dyspnea | 2 | 2010 | 76 | 0.100 |
Why?
|
| Hypotension | 1 | 2012 | 71 | 0.100 |
Why?
|
| Coronary Disease | 1 | 2013 | 261 | 0.100 |
Why?
|
| Adolescent | 3 | 2017 | 9341 | 0.090 |
Why?
|
| Adult | 7 | 2019 | 26922 | 0.090 |
Why?
|
| Heart Rate | 3 | 2008 | 496 | 0.090 |
Why?
|
| Systole | 2 | 2008 | 115 | 0.090 |
Why?
|
| Recurrence | 2 | 2011 | 1162 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 279 | 0.090 |
Why?
|
| Vascular Patency | 2 | 2020 | 131 | 0.080 |
Why?
|
| Acute Disease | 5 | 2009 | 854 | 0.080 |
Why?
|
| Respiratory System Agents | 1 | 2009 | 7 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 60 | 0.080 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2009 | 25 | 0.080 |
Why?
|
| Prevalence | 1 | 2013 | 1251 | 0.080 |
Why?
|
| Smoking | 1 | 2013 | 627 | 0.080 |
Why?
|
| Amyloid | 1 | 2009 | 95 | 0.080 |
Why?
|
| Cardiology | 1 | 2010 | 118 | 0.080 |
Why?
|
| Internationality | 1 | 2008 | 71 | 0.080 |
Why?
|
| Assisted Circulation | 1 | 2008 | 16 | 0.080 |
Why?
|
| Ventricular Function | 1 | 2008 | 53 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1397 | 0.080 |
Why?
|
| Diastole | 3 | 2018 | 144 | 0.080 |
Why?
|
| Prosthesis Design | 2 | 2019 | 307 | 0.070 |
Why?
|
| Pacemaker, Artificial | 1 | 2008 | 96 | 0.070 |
Why?
|
| Atrial Function | 1 | 2007 | 19 | 0.070 |
Why?
|
| Remission Induction | 1 | 2009 | 745 | 0.070 |
Why?
|
| Hypertension | 1 | 2013 | 746 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2007 | 37 | 0.070 |
Why?
|
| Blood Pressure Determination | 1 | 2007 | 61 | 0.070 |
Why?
|
| Critical Care | 1 | 2010 | 385 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2009 | 349 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 2014 | 1178 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 126 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2008 | 465 | 0.070 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2007 | 102 | 0.070 |
Why?
|
| Catheterization, Central Venous | 1 | 2007 | 116 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 974 | 0.070 |
Why?
|
| Physical Examination | 1 | 2007 | 150 | 0.070 |
Why?
|
| ROC Curve | 1 | 2008 | 781 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2010 | 591 | 0.060 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 112 | 0.060 |
Why?
|
| Respiration, Artificial | 1 | 2007 | 361 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1935 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2006 | 338 | 0.050 |
Why?
|
| Program Development | 1 | 2023 | 128 | 0.050 |
Why?
|
| Life Style | 1 | 2023 | 174 | 0.050 |
Why?
|
| Length of Stay | 2 | 2019 | 756 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2024 | 878 | 0.050 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 24 | 0.050 |
Why?
|
| Internship and Residency | 2 | 2007 | 1066 | 0.040 |
Why?
|
| Limb Salvage | 1 | 2020 | 37 | 0.040 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 295 | 0.040 |
Why?
|
| Vascular Stiffness | 1 | 2020 | 30 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 153 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2020 | 85 | 0.040 |
Why?
|
| Algorithms | 3 | 2017 | 1918 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 270 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2019 | 34 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2019 | 130 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2020 | 275 | 0.040 |
Why?
|
| Bioprosthesis | 1 | 2019 | 39 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 324 | 0.040 |
Why?
|
| American Heart Association | 1 | 2019 | 95 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 145 | 0.040 |
Why?
|
| Endocardium | 1 | 2018 | 98 | 0.040 |
Why?
|
| Tricuspid Valve | 1 | 2018 | 101 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2019 | 467 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 17 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 259 | 0.030 |
Why?
|
| Phlebography | 1 | 2017 | 70 | 0.030 |
Why?
|
| Animals | 3 | 2020 | 27690 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 471 | 0.030 |
Why?
|
| Education, Medical | 1 | 2019 | 244 | 0.030 |
Why?
|
| Cannula | 1 | 2016 | 52 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 875 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 589 | 0.030 |
Why?
|
| Aorta | 1 | 2017 | 291 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2014 | 11 | 0.030 |
Why?
|
| Pulmonary Alveoli | 1 | 2014 | 71 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1192 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 812 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2015 | 160 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2015 | 188 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 46 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 566 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 149 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2008 | 1141 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1499 | 0.020 |
Why?
|
| Furosemide | 1 | 2012 | 35 | 0.020 |
Why?
|
| Diuretics | 1 | 2012 | 76 | 0.020 |
Why?
|
| Infant | 1 | 2018 | 3183 | 0.020 |
Why?
|
| Sodium | 1 | 2012 | 334 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 671 | 0.020 |
Why?
|
| Edema, Cardiac | 1 | 2010 | 3 | 0.020 |
Why?
|
| Physical Exertion | 1 | 2010 | 38 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 792 | 0.020 |
Why?
|
| Dizziness | 1 | 2010 | 26 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2010 | 34 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 103 | 0.020 |
Why?
|
| Pulmonary Atelectasis | 1 | 2009 | 19 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 328 | 0.020 |
Why?
|
| Dobutamine | 1 | 2009 | 61 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 270 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 3426 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 452 | 0.020 |
Why?
|
| Heart, Artificial | 1 | 2008 | 9 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 419 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2007 | 63 | 0.020 |
Why?
|
| Body Surface Area | 1 | 2007 | 36 | 0.020 |
Why?
|
| Positive-Pressure Respiration | 1 | 2007 | 40 | 0.020 |
Why?
|
| Jugular Veins | 1 | 2007 | 74 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 85 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2007 | 154 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 198 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 680 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2007 | 102 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 866 | 0.020 |
Why?
|
| Mice | 1 | 2020 | 11932 | 0.020 |
Why?
|
| Observer Variation | 1 | 2007 | 615 | 0.020 |
Why?
|
| Organ Size | 1 | 2006 | 374 | 0.020 |
Why?
|
| Logistic Models | 1 | 2008 | 1216 | 0.010 |
Why?
|
| Patient Selection | 1 | 2008 | 682 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 791 | 0.010 |
Why?
|